Patients with stages I-III ( including inflammatory ) HER2-positive breast cancer were randomised to receive epirubicin ( E ) plus cyclophosphamide ( C ) 4 cycles followed by docetaxel ( D ) plus either T ( EC-DT ) or L ( EC-DL ) .